This article is more than 5 years old. Information may no longer be current.

Roche posts 8% increase in sales for 2009

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BASEL, Switzerland — Roche reported total sales of 49.05 billion Swiss francs for the full-year 2009, representing an 8% rise compared with sales reported during 2008, the company announced in a press release.

Despite fourth-quarter reductions in wholesaler inventory levels, the company's pharmaceuticals division reported full-year 2009 sales totaling 39 billion Swiss francs, representing an 8% gain compared with sales posted during the full-year 2008.

Roche partially attributed the growth to a 24% spike in sales of Lucentis (ranibizumab, Genentech) in the United States, which totaled 1.2 billion Swiss francs for the year. This was primarily due to a rise in injections administered to patients in the first and second year of treatment, growth in the number of patients treated for wet AMD and easier reimbursement, according to the release.

For the full-year 2010, Roche expects total sales to increase in the mid-single digit range.

Follow OSNSuperSite.com on Twitter.